Hypaconitine

Hypaconitine inhibits the KCNH2 current with an IC50 of 8.1 nM, and exhibits cardiotoxicity. Hypaconitine inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cell through the inhibition of NF-κB nuclear translocation. Hypaconitine acts as the neuromuscular blocker. Hypaconitine is orally active[1][2][3][4].

Product Specifications

CAS Number

[6900-87-4]

UNSPSC

12352005

Hazard Statement

H300

Target

Calcium Channel; NF-κB; Potassium Channel

Type

Natural Products

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Hypaconitine.html

Concentration

10mM

Purity

99.49

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CO[C@@H](CC1)C23[C@@](C[C@@]4(O)[C@@H]5OC(C6=CC=CC=C6)=O)([H])[C@@]5([H])[C@](OC(C)=O)([C@@H](O)[C@@H]4OC)C7C2N(C)C[C@@]1(COC)[C@@]3([H])[C@H]7OC

Molecular Formula

C33H45NO10

Molecular Weight

615.71

Precautions

H300

References & Citations

[1]Feng HT, et al., Hypaconitine inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses adhesion, migration, and invasion of lung cancer A549 cells. Chin J Nat Med. 2017 Jun;15 (6) :427-435. |[2]Xie S, et al., Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs. J Ethnopharmacol. 2015 May 26;166:375-9.|[3]Hsu SS, et al., Mechanism of action of a diterpene alkaloid hypaconitine on cytotoxicity and inhibitory effect of BAPTA-AM in HCN-2 neuronal cells. Clin Exp Pharmacol Physiol. 2021 May;48 (5) :801-810.|[4]Muroi M, et al., Blocking effects of hypaconitine and aconitine on nerve action potentials in phrenic nerve-diaphragm muscles of mice. Neuropharmacology. 1990 Jun;29 (6) :567-72.